Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2000

Open Access 01-11-2000 | Research article

The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)

Authors: Maarten C Kraan, Dhavalkumar D Patel, Jasper J Haringman, Malcolm D Smith, Helen Weedon, Michael J Ahern, Ferdinand C Breedveld, Paul P Tak

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Abstract

Paired synovial tissue samples were obtained from both clinically uninvolved (CU) and clinically involved (CI) knee joints of eight rheumatoid arthritis (RA) patients. In addition, biopsies were taken from five control subjects. We observed the expression of the chemokines CXCL8, CXCL9, CXCL10, CCL2 and CCL4 in CI and CU joints of RA patients. In particular, CXCL8 protein levels were specifically increased in CI joints compared with CU joints, which was confirmed by immunohistochemistry and in situ hybridization.
Literature
1.
Burmester GR, Stuhlmuller B, Keyszer G, Kinne G: Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?. Arthritis Rheum. 1997, 40: 5-18.PubMedCrossRef
2.
Koch AE, Burrows JC, Skoutelis A, Marder R, Domer PH, Anderson B, Leibovich SJ: Monoclonal antibodies detect monocyte/macrophage activation and differentiation antigens and identify functionally distinct subpopulations of human rheumatoid synovial tissue macrophages. Am J Pathol. 1991, 138: 165-173.PubMedPubMedCentral
3.
Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone EC: Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum. 1997, 40: 490-498.PubMedCrossRef
4.
5.
Mulherin D, FitzGerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 115-124.PubMedCrossRef
6.
Lindblad S, Klareskog L, Hedfors E, Forsum U, Sundstrom C: Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum. 1983, 26: 1321-1332.PubMedCrossRef
7.
Tak PP, Smeets TJM, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: Analysis of the synovial cellular infiltrate in early rheumatoid synovial tissue in relation to disease activity. Arthritis Rheum. 1997, 40: 217-225.PubMedCrossRef
8.
Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post W, 't Hart BA, Breedveld FC, Tak PP: Asymptomatic synovitis precedes clinical manifest arthritis. Arthritis Rheum. 1998, 41: 1481-1488.PubMedCrossRef
9.
Soden M, Rooney M, Cullen A, Whelan A, Feighery C, Bresnihan B: Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol. 1989, 28: 287-292.PubMedCrossRef
10.
Koch AE, Polverini PJ, Leibovich SJ: Functional heterogeneity of human rheumatoid synovial tissue macrophages. J Rheumatol. 1988, 15: 1058-1063.PubMed
11.
12.
Kunkel SL, Lukacs N, Kasama T, Strieter RM: The role of chemokines in inflammatory joint disease. J Leukoc Biol. 1996, 59: 6-12.PubMed
13.
Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 2000, 12: 121-127.PubMedCrossRef
14.
Koch AE, Kunkel SJ, Burrows JC: Synovial tissue macrophage as source of the chemotactic cytokine IL-8. J Immunol. 1991, 147: 2187-2195.PubMed
15.
Endo H, Akahoshi T, Nishimura A, Tonegawa M, Takagishi K, Kashiwazaki S, Matsushima K, Kondo H: Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints. Clin Exp Immunol. 1994, 96: 31-35.PubMedPubMedCentralCrossRef
16.
Akahoshi T, Endo H, Kondo H, Kashiwazaki S, Kasahara T, Mukaida N, Harada A, Matsushima K: Essential involvement of interleukin-8 in neutrophil recruitment in rabbits with acute experimental arthritis induced by lipopolysaccharide and interleukin-1. Lymphokine Cytokine Res. 1994, 13: 113-116.PubMed
17.
Loetscher M, Gerber B, Loetscher P: Chemokine receptor specific for IP-10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996, 184: 1101-1109.CrossRef
18.
Villiger PM, Terkeltaub R, Lotz M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol. 1992, 149: 722-727.PubMed
19.
Hachicha M, Naccache PH, McColl SR: Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med. 1995, 182: 2019-2025.PubMedCrossRef
20.
Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K, Kondo H, Kashiwazaki S, Matsushima K: Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Arthritis Rheum. 1993, 36: 762-771.PubMedCrossRef
21.
Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN: Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inhibitory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol. 1995, 101: 398-407.PubMedPubMedCentralCrossRef
22.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1987, 31: 315-324.CrossRef
23.
Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968, 37: 393-406.PubMed
24.
Tak PP, Lubbe van der A, Cauli A, Daha MR, Smeets TJM, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC: Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum. 1995, 38: 1457-1465.PubMedCrossRef
25.
Wikaningrum R, Highton J, Parker A, Coleman M, Hessian PA, Roberts-Thomson PJ, Ahern MJ, Smith MD: Pathogenic mechanisms in the rheumatoid nodule. Comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum. 1998, 41: 1793-1797.CrossRef
26.
Smith MD, Triantafillou S, Parker A, Wikaningrum R, Coleman M: A nonradioactive method of in situ hybridization that uses riboprobes and paraffin-embedded tissue and its combination with immunohistochemistry. Diagn Mol Pathol. 1997, 6: 34-41. 10.1097/00019606-199702000-00006.PubMedCrossRef
27.
Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP: Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology. 2000, 39: 43-49. 10.1093/rheumatology/39.1.43.PubMedCrossRef
28.
Kraan MC, Smith MD, Weedon H, Ahern MJ, Breedveld FC, Tak PP: Quantification of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis. 2000,
29.
Brennan FM, Cope AP, Katsikis P, Gibbons DL, Maini RM, Feldman M: Selective imunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis. Chem Immunol. 1995, 60: 48-60.PubMedCrossRef
30.
van der Loo AAJ, Arntz OJ, Bakker AC, van Lent PL, Jacobs MJ, van den Berg WB: Role of interleukin 1 in antigen induced exacerbations of murine arthritis. Am J Pathol. 1995, 146: 196-202.
31.
Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. Arthritis Rheum. 1988, 31: 480-486.PubMedCrossRef
32.
33.
Luster AD: Chemokines — chemotactic cytokines that mediate inflammation. N Engl JMed. 1999, 338: 436-445.
34.
Szekanecz Z, Strieter RM, Kunkel SL, Koch AE: Chemokines in rheumatoid arthritis. Springer Semin Immunopathol. 1998, 20: 115-132.PubMedCrossRef
35.
Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992, 90: 772-779.PubMedPubMedCentralCrossRef
36.
Beaulieu AD, McColl SR: Differential expression of two major cytokines produced by neutrophils, IL-8 and interleukin-1 receptor antagonist, in neutrophils isolated from the synovial fluid and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1994, 37: 855-859.PubMedCrossRef
37.
al-Mughales J, Blyth T, Hunter JA, Wilkinson PC: The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin Exp Immunol. 1996, 106: 230-236.PubMedPubMedCentralCrossRef
38.
Hatano Y, Kasama T, Iwabuchi H, Hanaoka R, Takeuchi HT, Jing L, Mori Y, Kobayashi K, Negishi M, Ide H, Adachi M: Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis. Ann Rheum Dis. 1999, 58: 297-302.PubMedPubMedCentralCrossRef
39.
Peichl P, Pursch E, Broll H, Lindley IJ: Anti IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol Int. 1999, 18: 141-145.PubMedCrossRef
40.
Lisignoli G, Toneguzzi S, Pozzi C, Piacentini A, Grassi F, Feruzzi A, Gualtieri G, Facchini A: Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin Exp Immunol. 1999, 116: 371-378.PubMedPubMedCentralCrossRef
41.
Palacios I, Lopez-Armada MJ, Hernandez P, Sanchez-Pernaute O, Gutierrez S, Miguelez R, Martinez J, Egido J, Herrero-Beaumont G: Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin Exp Immunol. 1998, 111: 588-596.PubMedPubMedCentralCrossRef
42.
Koch AE, Kunkel SL, Shah MR, Fu R, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Strieter RM: Macrophage inflammatory protein-1 beta: a C–C chemokine in osteoarthritis. Clin Immunol Immunopathol. 1995, 77: 307-314. 10.1006/clin.1995.1157.PubMedCrossRef
43.
Patel DD, Zachariah JP, Whichard LP: CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol. 2000,
44.
Jiang Y, Beller DI, Frendl G, Graves DT: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine expression and cytokine production in human monocytes. J Immunol. 1992, 148: 2423-2428.PubMed
45.
Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K: Selective acumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol. 1999, 11: 553-559.PubMedCrossRef
46.
Tanaka Y, Fujii K, Hubscher S, Aso M, Takazawa A, Saito K, Ota T, Eto S: Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. Arthritis Rheum. 1998, 41: 1365-1377.PubMedCrossRef
47.
Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T-cell in initiating and maintaining the chronic synovitis in rheumatoid arthritis. Arthritis Rheum. 1992, 35: 729-735.PubMedCrossRef
48.
Iannone F, Carrigol VM, Kingsley GH, Panayi GS: Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol. 1994, 24: 2706-2713.PubMedCrossRef
49.
Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, Takahashi Y, Yokoi K, Mukaida N, Matsushima K: Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leukoc Biol. 1997, 62: 444-449.PubMed
50.
Youssef PP, Cormack J, Evill CA, Peter DT, Roberts-Thomson PJ, Ahern MJ, Smith MD: Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Arthritis Rheum. 1996, 39: 216-225.PubMedCrossRef
51.
Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ, Ahern MJ, Smith MD: Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum. 1998, 40: 1400-1408.CrossRef
52.
Bertazzolo N, Punzi L, Pianon M, Cesaro G, Todesco S: Interrelationship between interleukin 8 and neutrophils in synovial fluid of crystal-induced arthritis. J Rheumatol. 1994, 21: 1776-1777.PubMed
53.
Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern J, Smith MD: Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 1970-1979.PubMedCrossRef
54.
Smith RE, Hogaboam CM, Strieter RM, Lukacs NW, Kunkel SL: Cell-to-cell and cell-to-matrix interactions mediate chemokine expression: an important component of the inflammatory lesion. J Leukoc Biol. 1997, 62: 612-619.PubMed
55.
Snyderman R: Pharmacoligic manipulation of leucocyte chemotaxis. Present kwowledge and future trends. Am J Med. 1983, 75: 10-18.PubMedCrossRef
56.
Tiku K, Tiku ML, Skosey JL: Interleukin-1 production by human polymorphonuclear neutrophils. J Immunol. 1986, 36: 3677-3685.
57.
Dubravec DB, Spriggs DR, Mannick JA, Rodrick ML: Circulation of human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc Natl Acad Sci USA. 1990, 87: 6758-6761.PubMedPubMedCentralCrossRef
58.
Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M: Phagocytosing neutrophils produce and release high amounts of neutrophil-activating peptide 1/interleukin-8. J Exp Med. 1991, 173: 771-774.PubMedCrossRef
59.
Kettritz R: IL-8 and neutrophils. Kidney Int. 53: 84-91. 10.1046/j.1523-1755.1998.00741.x.
60.
Mukaida N, Matsumoto T, Yokoi K, Harada A, Matsushima K: Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflamm Res. 1998, 47: S151-S157.PubMedCrossRef
61.
Gao IK, Leins C, Bohlen H, Heilig B, Lemmel EM: Inhibition of interleukin-8 synthesis by intraarticular methotrexate therapy in patients with rheumatoid arthritis. Z Rheumatol. 1999, 57: 95-100.CrossRef
Metadata
Title
The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)
Authors
Maarten C Kraan
Dhavalkumar D Patel
Jasper J Haringman
Malcolm D Smith
Helen Weedon
Michael J Ahern
Ferdinand C Breedveld
Paul P Tak
Publication date
01-11-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar141

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue

Paper Report

CD30 involvement in self tolerance of T cells

Paper Report

New receptor critical for BAFF-mediated B cell survival

Paper Report

GI toxicity of celecoxib vs traditional NSAIDs

Paper Report

Mutations in the WISP3gene cause PPD

Paper Report

CD44 and Fas

Paper Report

Risk for hip OA in siblings
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits